<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">For the time being, immunoglobulin G has been administered in COVID-19 critical patients as therapy [
 <xref ref-type="bibr" rid="CR121">121</xref>, 
 <xref ref-type="bibr" rid="CR122">122</xref>]. FcR has a role in pulmonary inflammation; hence blocking of FcR activation can reduce inflammatory damage in COVID-19. Thus intravenous use of immunoglobulins can prove helpful in the therapy of SARS-CoV-2 induced pulmonary inflammation [
 <xref ref-type="bibr" rid="CR123">123</xref>].
</p>
